Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Ashley L. Ward, MD
MacroGenics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
42 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Liverpool Hospital
Liverpool, New South Wales, Australia
- Monash Health, Medical Oncology Department
Ruse, New South Wales, Australia
- Royal North Shore Hospital
Sydney, New South Wales, Australia
- Calvary Mater Newcastle
Waratah, New South Wales, Australia
- Icon Cancer Centre Southport
Southport, Queensland, Australia
- Andrew Love Cancer Centre, Barwon Health
Geelong, Victoria, Australia
- Fiona Stanley Hospital
Murdoch, Western Australia, Australia
- Complex Oncology Center Ruse Ltd.
Dobrich, Bulgaria
- Mhat Serdica
Panagyurishte, Bulgaria
- Mbal Uni Hospital
Pleven, Bulgaria
- Coc Dobrich
Sofia, Bulgaria
- Mhat Nadezhda, Medical Oncology
Sofia, Bulgaria
- Umhat Georgi Stranski Medical Oncology Department
Sofia, Bulgaria
- Umhat Tsarisa Yoanna - Isul
Sofia, Bulgaria
- Bajcsy-Zsilinszky Korhaz
Budapest, Hungary
- Uzsoki Street Hospital
Budapest, Hungary
- Dept of Oncology, University of Debrecen
Debrecen, Hungary
- Dept of Oncology, Bekec County Hosp
Gyula, Hungary
- Dept of Oncology, Tolna County Hospital
Szekszárd, Hungary
- the Ewa Pilecka Department of Clinical Oncology
Bialystok, Poland
- Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
- I Clinics of Radiotherapy and Chemiotherapy; the Maria Sklodowska-Curie National Research Institute of Oncology
Gliwice, Poland
- Biokinetica
Józefów, Poland
- Clinics of Head and Neck Cancer, the Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, Poland
- Complejo Hospitalario Universitario de Badajoz
Badajoz, Spain
- Hospital Clínic de Barcelona
Barcelona, Spain
- Hospital Universitario Vall D'Hebrón
Barcelona, Spain
- Hospital Clínico San Carlos
Madrid, Spain
- Clinica Universidad de Navarra
Pamplona, Spain
- Hospital Universitario Virgen de la Macarena
Seville, Spain
- Communal Non-Profit Enterprise "city Clinical Hospital#4" of Dnipro City
Dnipro, Ukraine
- Communal Non-Profit Enterprise "regional Center of Oncology", Oncosurgical Department of Head and Neck
Kharkiv, Ukraine
- Communal Non-Profit Enterprise "regional Clinical Oncology Center of Kirovohrad Regional Council",
Kropyvnytskyi, Ukraine
- Kyiv City Clinical Oncological Centre
Kyiv, Ukraine
- Municipal Non-Profit Enterprise of Sumy Regional Council "sumy Regional Clinical Oncology Dispensary"
Sumy, Ukraine
- Communal Nonprofit Enterprise Podilsky Regional Center of Oncology
Vinnytsia, Ukraine
- University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- University of North Carolina - Lineberger Cancer Center
Chapel Hill, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Mar 2021
- Primary completion
- 29 Jul 2022
- Completion
- 29 Jul 2022
- Last update posted
- 20 Dec 2023
- Registered enrollment
- 62
- Registry id
- NCT04634825
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.